Venus Medtech
Manufacturing · China · 501-1,000 Employees
View Company Info for Free
Overview
Headquarters
room 201shuiyou bldg no. 3738 Nanhuan Bi...Phone Number
+86 57186759022Website
www.venusmedtech.comRevenue
$45.9 MillionIndustry
ZI Rank: 1
Signal Type
Dec
Jan
Feb
Mar
Apr
May
ZI Rank
1
2
1
1
1
1
About Venus Medtech
Venus Medtech (Hangzhou) Inc. was founded in 2009 to focus on the design, development and commercialization of transcatheter heart valve products. The Company is the leading transcatheter heart valve medical device player in China in terms of implantation volume in 2018. According to Frost & Sullivan, the Company had a 79.3% market share in China by implantation volume of transcatheter aortic heart valve replacement ("TAVR") products in 2018. Its self-developed product, VenusA-Valve, is the first TAVR product approved by the National Medical Products Administration ("NMPA") and commercialized in China. As the pioneer in the transcatheter heart valve industry in China, the Company enjoys first mover advantages. The Company believes that its first mover advantages, together with its comprehensive product pipeline covering all four heart valves, robust intellectual property portfolio with 193 issued patents and 196 patent applications as of November 18, 2019, and visionary management teamRead more
Venus Medtech Org Chart
Get the full picture
Sign in to uncover key details.
OG
Manager, Clinical Trial
DA
Clinical Manager
Get the full picture
Sign in to uncover key details.
Sell smarter with deeper company insights.
ZoomInfo gives you access to real-time firmographics, buying signals, org charts, and decision-makers - helping your GTM teams prioritize accounts, personalize outreach with AI-driven automation, and close deals faster.
Is Venus Medtech your ideal customer? 
Let us give you the heads up on whether it's a good time to reach out
Product Launch: Get notified when Venus Medtech launches new products
Website visits: Recent activity has been detected on your website
Click to see if Venus Medtech had a recent Job posting/layoffs
Funding: Get notified immidiatlly once Venus Medtech has new funding data
Venus Medtech, which may be a good buyer, showed buying intent in Masked Content Topic
Competitive Alert! Recent activity has been detected by your competitor Masked Content
Earning: See what the market has to say on Venus Medtech recently announced quarterly report
Check out if Venus Medtech is spiking on competitors!
Congratulate Masked Content for being promoted to Masked Content at Venus Medtech
Check if Venus Medtech has recently received funding, and reach out quickly before it becomes old news!
Recommended Actions
Find VP level buyers at Venus Medtech
Find more new buyers
Company Profile Activity
Activity Insights
Venus Medtech is experiencing very low activity levels compared to other companies in the Manufacturing sector.
What does this means?
Venus Medtech is drawing exceptional interest within the Manufacturing industry, suggesting notable developments or strong market momentum, learn more about Venus Medtech.
Venus Medtech financials insights
Gather financial insights about Venus Medtech, including details on funding rounds, investors, total funding, and acquisitions, to gain a comprehensive understanding of their financial strategy.
2016
Private Equity
$37M
Venus Medtech Tech Stack
A closer look at the technologies used by Venus Medtech
Most Recent Scoops
Person-Based
Person-Based
New Hire
Executive Move
Executive Moves, New Hire
New Hire
Executive Move
Venus Medtech has announced that Shakeel Osman has joined the company as Senior VP, Sales (Europe). Previously, Osman was General Manager (UK) & Vice President, Sales (Middle East, Asia & Africa) for Occlutech Medical Devices.
Mergers & Acquisitions (M&A)
Venus Medtech News & Media
Cardiovalve Submits CE File for Approval Following Successful TARGET Study Completion
Exciting Data on Cardiovalve Tricuspid Valve Replacement Device Presented at PCR London Valves 2025 meeting. LONDON, Nov. 17, 2025 /PRNewswire/ -- Venus Medtech (Hangzhou) Inc. (2500.HK) today announced that Cardiovalve has submitted the CE technical file for its transcatheter tricuspid...Cardiovalve Submits CE File for Approval Following Successful TARGET Study Completion
Exciting Data on Cardiovalve Tricuspid Valve Replacement Device Presented at PCR London Valves 2025 meeting. LONDON, Nov. 17, 2025 /PRNewswire/ -- Venus Medtech (Hangzhou) Inc. (2500.HK) today announced that Cardiovalve has submitted the CE technical file for its transcatheter tricuspid...Cardiovalve Completes TARGET Study Enrollment for CE Registration Study for Tricuspid Valve Replacement
The Company Advances Toward European CE Mark Submission with 150 Patients Enrolled; On Track for 2027 Commercial Launch HANGZHOU, China, Oct. 25, 2025 /PRNewswire/ -- Venus Medtech (Hangzhou) Inc. (2500.HK, hereinafter referred to as the "Company") today announced the successful completion of patient enrollment in the Cardiovalve TARGET study for Transcatheter Tricuspid Valve Replacement (TTVR), with a total of 150 patients enrolled. The completion of enrollment marks a major milestone toward EuVenus Medtech Hangzhou Inc. - Product Pipeline Analysis Report 2025
Provides actionable insights, profiling the company's pipeline products, and enhancing competitive strategy development for stakeholders Provides actionable insights, profiling the company's pipeline products, and enhancing competitive strategy development for stakeholders
Read more news
Top Manufacturing Companies
Top companies in Canada by revenue
Top companies in Australia by revenue
Frequently Asked Questions Regarding Venus Medtech
Sign Up For FreeTo access detailed company insights
Venus Medtech (Hangzhou) Inc. was founded in 2009 to focus on the design, development and commercialization of transcatheter heart valve products. The Company is the leading transcatheter heart valve medical device player in China in terms of implantation volume in 2018. According to Frost & Sullivan, the Company had a 79.3% market share in China b... Read More
